BDRX Stock Overview
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Biodexa Pharmaceuticals Plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.62 |
52 Week High | US$36.80 |
52 Week Low | US$0.72 |
Beta | 1.44 |
1 Month Change | 17.39% |
3 Month Change | -39.55% |
1 Year Change | -95.20% |
3 Year Change | -99.96% |
5 Year Change | -99.99% |
Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
BDRX | US Biotechs | US Market | |
---|---|---|---|
7D | 52.9% | 0.9% | 0.2% |
1Y | -95.2% | 11.0% | 28.1% |
Return vs Industry: BDRX underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: BDRX underperformed the US Market which returned 28.8% over the past year.
Price Volatility
BDRX volatility | |
---|---|
BDRX Average Weekly Movement | 29.6% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BDRX's share price has been volatile over the past 3 months.
Volatility Over Time: BDRX's weekly volatility (30%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 27 | Stephen Stamp | https://www.biodexapharma.com |
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.
Biodexa Pharmaceuticals Plc Fundamentals Summary
BDRX fundamental statistics | |
---|---|
Market cap | US$2.25m |
Earnings (TTM) | -US$10.30m |
Revenue (TTM) | US$667.65k |
6.4x
P/S Ratio-0.4x
P/E RatioIs BDRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BDRX income statement (TTM) | |
---|---|
Revenue | UK£529.00k |
Cost of Revenue | UK£4.95m |
Gross Profit | -UK£4.42m |
Other Expenses | UK£3.74m |
Earnings | -UK£8.16m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.12 |
Gross Margin | -835.54% |
Net Profit Margin | -1,543.10% |
Debt/Equity Ratio | 0% |
How did BDRX perform over the long term?
See historical performance and comparison